Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Josh J Carlson

Showing results (31-40 of 106) with videos related to

Pageof 11
Sort By:
Pharmacoeconomics|October 13, 2010
Cost effectiveness of pharmacogenomics: a critical and systematic reviewWilliam B Wong, Josh J Carlson, Rahber Thariani, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 13, 2019
Are There Different Evidence Thresholds for Genomic Versus Clinical Precision Medicine? A Value of Information-Based Framework Applied to Antiplatelet Drug TherapyGregory F Guzauskas, Anirban Basu, Josh J Carlson, et al.
Leukemia & Lymphoma|April 15, 2016
Indirect costs and workplace productivity loss associated with non-Hodgkin lymphomaJustin S Yu, Ryan N Hansen, Adriana Valderrama, et al.
Pharmacoeconomics|September 7, 2019
Demand for Precision Medicine: A Discrete-Choice Experiment and External Validation StudyDean A Regier, David L Veenstra, Anirban Basu, et al.
Journal of Managed Care & Specialty Pharmacy|November 30, 2020
The use of real-world evidence in ICER's scoping process and clinical evidence assessmentsBoshen Jiao, David L Veenstra, Woojung Lee, et al.
Journal of Medical Economics|April 11, 2014
Targeted erlotinib for first-line treatment of advanced non-small cell lung cancer: a budget impact analysisPreeti S Bajaj, David L Veenstra, Hans-Peter Goertz, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|July 24, 2008
The potential clinical and economic outcomes of pharmacogenomic approaches to EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancerJosh J Carlson, Louis P Garrison, Scott D Ramsey, et al.
Journal of Comparative Effectiveness Research|August 22, 2022
Comparative effectiveness of larotrectinib versus entrectinib for the treatment of metastatic <i>NTRK</i> gene fusion cancersKangho Suh, Josh J Carlson, Fang Xia, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|October 26, 2005
Economic analyses of human genetics services: a systematic reviewJosh J Carlson, Nora Beidler Henrikson, David L Veenstra, et al.
JCO Precision Oncology|March 28, 2025
Real-World Molecular Testing Rates and Patterns in Patients With Primary Advanced or Recurrent Endometrial Cancer in the United StatesYilin Chen, Solomon J Lubinga, Troy Williams, et al.
Pageof 11

Showing results (31-40 of 106) with videos related to

Sort By:
Pageof 11
Pharmacoeconomics|October 13, 2010
Cost effectiveness of pharmacogenomics: a critical and systematic reviewWilliam B Wong, Josh J Carlson, Rahber Thariani, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 13, 2019
Are There Different Evidence Thresholds for Genomic Versus Clinical Precision Medicine? A Value of Information-Based Framework Applied to Antiplatelet Drug TherapyGregory F Guzauskas, Anirban Basu, Josh J Carlson, et al.
Leukemia & Lymphoma|April 15, 2016
Indirect costs and workplace productivity loss associated with non-Hodgkin lymphomaJustin S Yu, Ryan N Hansen, Adriana Valderrama, et al.
Pharmacoeconomics|September 7, 2019
Demand for Precision Medicine: A Discrete-Choice Experiment and External Validation StudyDean A Regier, David L Veenstra, Anirban Basu, et al.
Journal of Managed Care & Specialty Pharmacy|November 30, 2020
The use of real-world evidence in ICER's scoping process and clinical evidence assessmentsBoshen Jiao, David L Veenstra, Woojung Lee, et al.
Journal of Medical Economics|April 11, 2014
Targeted erlotinib for first-line treatment of advanced non-small cell lung cancer: a budget impact analysisPreeti S Bajaj, David L Veenstra, Hans-Peter Goertz, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|July 24, 2008
The potential clinical and economic outcomes of pharmacogenomic approaches to EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancerJosh J Carlson, Louis P Garrison, Scott D Ramsey, et al.
Journal of Comparative Effectiveness Research|August 22, 2022
Comparative effectiveness of larotrectinib versus entrectinib for the treatment of metastatic <i>NTRK</i> gene fusion cancersKangho Suh, Josh J Carlson, Fang Xia, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|October 26, 2005
Economic analyses of human genetics services: a systematic reviewJosh J Carlson, Nora Beidler Henrikson, David L Veenstra, et al.
JCO Precision Oncology|March 28, 2025
Real-World Molecular Testing Rates and Patterns in Patients With Primary Advanced or Recurrent Endometrial Cancer in the United StatesYilin Chen, Solomon J Lubinga, Troy Williams, et al.
Pageof 11